Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease
Frits ME Franssen1, Martijn A Spruit1, Emiel FM Wouters1,2
1Program Development Center, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands; 2Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
Background: Polypharmacy of respiratory medications is commonly observed in patients with chronic obstructive pulmonary disease (COPD). The aims of this study were to investigate determinants of polypharmacy and to study the consistency of actual respiratory drug use with current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in pulmonary rehabilitation candidates with COPD.
Methods: Data were extracted from the records of all patients with a diagnosis of COPD referred for pulmonary rehabilitation to CIRO+ between 2005 and 2009. Use of respiratory medications, self-reported COPD exacerbations, lung function, blood gases, exercise capacity, Medical Research Council (MRC) dyspnea grade, and St George’s Respiratory Questionnaire (SGRQ) were recorded as part of assessment of health status.
Results: In total, 1859 COPD patients of mean age (± standard deviation) 64.3 ± 9.7 years and with a forced expiratory volume in one second (FEV1) of 44.7% ± 18.2% were included. On average, patients used 3.5 ± 1.5 respiratory medications; this number increased with increasing GOLD stage, MRC score, and SGRQ scores. FEV1 (% predicted), SGRQ, and number of recent exacerbations were independent determinants of polypharmacy. Use of long-acting bronchodilators and inhaled corticosteroids was substantial and comparable in all GOLD stages. Use of corticosteroids was not restricted to patients with frequent exacerbations.
Conclusion: Polypharmacy of respiratory medications is common in COPD patients with persistent symptoms. In addition to severity of disease, health status is an independent predictor of polypharmacy. Actual drug use in COPD patients referred for pulmonary rehabilitation is partially inconsistent with current GOLD guidelines.
Keywords: chronic obstructive pulmonary disease, management, pharmacotherapy, polypharmacy, pulmonary rehabilitation, respiratory drug use
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML]
Readers of this article also read:
Gold nanorods/mesoporous silica-based nanocomposite as theranostic agents for targeting near-infrared imaging and photothermal therapy induced with laser
Liu Y, Xu M, Chen Q, Guan G, Hu W, Zhao X, Qiao M, Hu H, Liang Y, Zhu H, Chen D
Published Date: 28 July 2015
Sustained release of VH and rhBMP-2 from nanoporous magnesium–zinc–silicon xerogels for osteomyelitis treatment and bone repair
Li FQ, Wu W, Xiang L, Weng G, Hong H, Jiang H, Qian J
Published Date: 22 June 2015
Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies
Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J
Published Date: 22 April 2015
Factors associated with group bullying and psychopathology in elementary school students using child-welfare facilities
Kim JW, Lee K, Lee YS, Han DH, Min KJ, Song SH, Park GN, Lee JY, Kim JO
Published Date: 7 April 2015
Ortega FG, Fernández-Baldo MA, Fernández JG, Serrano MJ, Sanz MI, Diaz-Mochón JJ, Lorente JA, Raba J
Published Date: 16 March 2015
Kinematic analysis of motor strategies in frail aged adults during the Timed Up and Go: how to spot the motor frailty?
Hassani A, Kubicki A, Brost V, Mourey F, Yang F
Published Date: 26 February 2015
Chen Y, Tang C, Zhang J, Gong M, Su B, Qiu F
Published Date: 23 January 2015
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
Prakash A, Babu KS, Morjaria JB
Published Date: 7 January 2015
Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells
Cui FB, Liu Q, Li RT, Shen J, Wu PY, Yu LX, Hu WJ, Wu FL, Jiang CP, Yue GF, Qian XP, Jiang XQ, Liu BR
Published Date: 13 May 2014
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
Published Date: 6 August 2010